New York State Teachers Retirement System Cuts Stake in Charles River Laboratories International, Inc. $CRL

New York State Teachers Retirement System reduced its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 0.2% during the second quarter, according to its most recent filing with the SEC. The fund owned 40,710 shares of the medical research company’s stock after selling 74 shares during the quarter. New York State Teachers Retirement System owned 0.08% of Charles River Laboratories International worth $6,177,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in CRL. GAMMA Investing LLC lifted its holdings in Charles River Laboratories International by 61.6% during the first quarter. GAMMA Investing LLC now owns 1,398 shares of the medical research company’s stock valued at $210,000 after purchasing an additional 533 shares during the last quarter. Janney Montgomery Scott LLC lifted its holdings in Charles River Laboratories International by 13.1% during the first quarter. Janney Montgomery Scott LLC now owns 44,500 shares of the medical research company’s stock valued at $6,698,000 after purchasing an additional 5,148 shares during the last quarter. QRG Capital Management Inc. lifted its holdings in Charles River Laboratories International by 12.7% during the first quarter. QRG Capital Management Inc. now owns 1,557 shares of the medical research company’s stock valued at $234,000 after purchasing an additional 175 shares during the last quarter. State of Alaska Department of Revenue lifted its holdings in Charles River Laboratories International by 1.0% during the first quarter. State of Alaska Department of Revenue now owns 15,914 shares of the medical research company’s stock valued at $2,395,000 after purchasing an additional 150 shares during the last quarter. Finally, Blue Trust Inc. lifted its holdings in Charles River Laboratories International by 60.1% during the first quarter. Blue Trust Inc. now owns 2,407 shares of the medical research company’s stock valued at $362,000 after purchasing an additional 904 shares during the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Stock Up 2.0%

CRL stock opened at $178.37 on Monday. The company has a current ratio of 1.36, a quick ratio of 1.10 and a debt-to-equity ratio of 0.69. The company’s 50 day moving average is $160.84 and its 200 day moving average is $148.34. The stock has a market cap of $8.78 billion, a price-to-earnings ratio of -134.11, a price-to-earnings-growth ratio of 4.77 and a beta of 1.50. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $230.02.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, August 6th. The medical research company reported $3.12 earnings per share for the quarter, topping the consensus estimate of $2.50 by $0.62. The company had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $983.76 million. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. Charles River Laboratories International’s revenue for the quarter was up .6% compared to the same quarter last year. During the same period in the prior year, the business earned $2.80 earnings per share. Sell-side analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on CRL. JPMorgan Chase & Co. upped their price objective on shares of Charles River Laboratories International from $145.00 to $160.00 and gave the company a “neutral” rating in a report on Thursday, August 7th. Wall Street Zen upgraded Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, October 15th. Citigroup upgraded Charles River Laboratories International from a “neutral” rating to a “buy” rating and upped their price target for the company from $150.00 to $200.00 in a research report on Wednesday, July 9th. Barclays upgraded Charles River Laboratories International from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $165.00 to $195.00 in a research report on Thursday, October 2nd. Finally, Mizuho upped their price target on Charles River Laboratories International from $155.00 to $174.00 and gave the company a “neutral” rating in a research report on Friday. Eight analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $181.29.

Insider Buying and Selling at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 800 shares of the company’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $157.60, for a total value of $126,080.00. Following the transaction, the executive vice president directly owned 24,116 shares in the company, valued at approximately $3,800,681.60. This represents a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).